Dark

Check out our Level2View

AZRX
AzurRx BioPharma, Inc. Common Stock
stock NASDAQ

Inactive

Sep 21, 2021

3.45USD+2.071%(+0.07)629,030

Pre-market

0.00USD-100.000%(-3.38)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

12:48PM EDT AzurRx BioPharma To Change Corporate Name To First Wave BioPharma Today; Will Trade Under Symbol 'FWBI' Starting Sept. 22 Benzinga

12:48PM EDT AzurRx BioPharma to Change Corporate Name to First Wave BioPharma GlobeNewswire Inc

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 16, 2021

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 14, 2021

10:57AM EDT Shares of AzurRx BioPharma, Inc. (AZRX) are gaining over 14% on Tuesday morning. The previous day, AzurRx agreed to buy First Wave Bio, Inc. in a stock and cash deal valued at $229 million. RTTNews

10:11AM EDT Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August Benzinga

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

07:30AM EDT AzurRx BioPharma CEO Issues Letter to Shareholders Regarding GlobeNewswire Inc

07:12AM EDT AzurRx BioPharma To Acquire First Wave Bio For $229M Benzinga

Sep 13, 2021

09:19AM EDT AzurRx BioPharma Announces Reverse Merger With First Wave Bio Benzinga

06:29AM EDT AzurRx BioPharma, Inc. (AZRX) has agreed to acquire First Wave Bio, Inc. in a stock and cash deal valued at $229 million. AzurRx will change its corporate name to First Wave BioPharma Inc., and will trade common shares on Nasdaq under ticker symbol, FWBI. RTTNews

06:15AM EDT AzurRx BioPharma Agrees To Buy First Wave Bio In Stock And Cash Transaction Valued At $229 Mln RTTNews

06:05AM EDT AzurRx BioPharma Announces Acquisition Of First Wave Bio For $229M Benzinga

06:00AM EDT AzurRx BioPharma to be renamed First Wave BioPharma and trade under new NASDAQ ticker symbol, FWBI GlobeNewswire Inc

Sep 10, 2021

07:36PM EDT AzurRx BioPharma Announces Reverse Stock Split; 1-For-10 Split Benzinga

12:45PM EDT AzurRx BioPharma Announces Reverse Stock Split GlobeNewswire Inc

09:22AM EDT AzurRx BioPharma Inc. (AZRX) said that it has activated seven new clinical trial sites in India for phase 2 RESERVOIR Trial evaluating niclosamide for the treatment of COVID-19 gastrointestinal infections. RTTNews

08:36AM EDT AzurRx BioPharma Activates New Clinical Trial Sites In India For Phase 2 RESERVOIR Trial Of FW-1022 RTTNews

08:31AM EDT AzurRx BioPharma Activates New Clinical Trial Sites In India For Phase 2 RESERVOIR Trial Evaluating Niclosamide For Treatment of COVID-19 Gastrointestinal Infections Benzinga

08:30AM EDT AzurRx BioPharma Activates New Clinical Trial Sites in India for GlobeNewswire Inc

Sep 9, 2021

09:40AM EDT AzurRx BioPharma Inc. (AZRX) said that an independent data monitoring committee or DMC approved initiating patient enrollment in Part 2 of the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections. RTTNews

08:50AM EDT AzurRx BioPharma Announces Results From Independent Data Monitoring Committee Review Of Safety Data From Part 1 Of RESERVOIR Phase 2 Clinical Trial Of Niclosamide; Review Concluded With Recommendation To Continue Trial As Planned Benzinga

08:40AM EDT AzurRx BioPharma Announces Positive Data From Part 1 Of RESERVOIR Phase 2 Trial Of Niclosamide RTTNews

08:30AM EDT Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned GlobeNewswire Inc

Sep 8, 2021

08:39AM EDT AzurRx BioPharma Submits IND Application For Niclosamide RTTNews

08:30AM EDT AzurRx BioPharma Submits an Investigational New Drug Application GlobeNewswire Inc

Sep 7, 2021

04:30PM EDT AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd GlobeNewswire Inc

Aug 18, 2021

12:40PM EDT AzurRx BioPharma Announces Phase 2 MS1819 Combination Therapy Trial Met Primary And Secondary Outcome Measure Endpoints Benzinga

12:20PM EDT EXCLUSIVE: AzurRx President & CEO Comments On Phase 2 MS1819 Trial, Tells Benzinga ''We anticipate that this new formulation could be used to treat patients with severe EPI, either as a stand-alone monotherapy or as a combination therapy with PERT' Benzinga

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

07:13AM EDT AzurRx BioPharma Announces Phase 2 MS1819 Combination Therapy Trial Met Primary End Secondary Outcome Measure Endpoints Benzinga

07:06AM EDT -- MS1819 and PERT combination therapy achievesprimaryand secondary outcome measure endpoints -- Study data indicates clinically meaningfulimprovement in coefficient of fat absorption(CFA) primary endpoint -- 20-patient study suggests combination therapy may benefit cystic fibrosis patients with severe EPI GlobeNewswire Inc

Aug 17, 2021

07:04AM EDT AzurRx BioPharma Highlights WHO Publication Of 'Adrulipase Alfa' As International Nonproprietary Name For MS1819 Benzinga

07:00AM EDT AzurRx BioPharma Announces WHO Publication of GlobeNewswire Inc

Aug 16, 2021

08:00AM EDT AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies forgastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRxs Board to seven members. GlobeNewswire Inc

Aug 12, 2021

07:08AM EDT AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Benzinga

07:00AM EDT AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 GlobeNewswire Inc

Aug 10, 2021

07:03AM EDT AzurRx BioPharma Adds New Clinical Trial Sites In Ukraine For Phase 2 RESERVOIR Clinical Trial Of Niclosamide For The Treatment Of COVID-19 Gastrointestinal Infections Benzinga

07:00AM EDT AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for GlobeNewswire Inc

Aug 2, 2021

06:17AM EDT HC Wainwright & Co. Maintains Buy on AzurRx BioPharma, Lowers Price Target to $2 Benzinga

Jul 27, 2021

04:30PM EDT AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal GlobeNewswire Inc

Jul 26, 2021

01:54PM EDT AzurRx BioPharma shares were trading higher after Hawk Point Media Group issued a press release highlighting the company's COVID-19 pipeline. Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 22, 2021

04:52PM EDT AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

10:00AM EDT FMW Medias New to The Street /Newsmax TV announces its TV airing of this weeks, Sunday, July 18, 2021, broadcasting line-up of its national syndicated 1- hour show, 10-11AM ET. GlobeNewswire Inc

Jun 17, 2021

05:03PM EDT AzurRx BioPharma Says On June 15 Co Received Letter From Nasdaq Saying Co Is Not In Compliance With Minimum Bid Price Benzinga

Jun 8, 2021

07:00AM EDT AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital GlobeNewswire Inc

Jun 7, 2021

08:06AM EDT AzurRx BioPharma, Inc. (AZRX), a clinical stage biopharmaceutical company focused on gastrointestinal diseases, announced Monday the administration of the first dose of FW-1022 to a volunteer in the ongoing Phase 2 RESERVOIR clinical trial. The trial will evaluate niclosamide's ability to target SARS-CoV-2 in the GI tract. RTTNews

07:12AM EDT AzurRx Doses First Patient In Phase 2 Trial Of Niclosamide For COVID-19 Gastrointestinal Infections RTTNews

07:04AM EDT AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Benzinga

07:00AM EDT RESERVOIR trial to evaluate niclosamides ability to target SARS-CoV-2 in the GI tract GlobeNewswire Inc

Jun 4, 2021

02:01PM EDT FMW Medias New to The Street TV broadcasting its national syndicated 1- hour show, Sunday, June 06, 2021 on NEWSMAX TV from 10-11AM ET. GlobeNewswire Inc

01:02PM EDT FMW Medias New to The Street TV broadcasting its national syndicated 1- hour show, Sunday, May 16, 2021 on NEWSMAX TV from 10-11AM ET. GlobeNewswire Inc

May 19, 2021

07:30AM EDT AzurRx BioPharma, Inc. (NASDAQ: AZRX), (AzurRx or the Company), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at the Rocky Mountain Microcap Conference on May 26, 2021. GlobeNewswire Inc

May 14, 2021

03:00PM EDT FMW Medias New to The Street TV broadcasting its national syndicated 1- hour show, Sunday, May 16, 2021 on NEWSMAX TV from 10-11AM ET. GlobeNewswire Inc

02:45PM EDT FMW Media Corp. announces that its New To The Street business TV show will feature AzurRx BioPharma, Inc. (NASDAQ: AZRX) in a 3-part TV series featured across its entire syndicated linear television platform. GlobeNewswire Inc

May 13, 2021

08:49AM EDT AzurRx BioPharma Stock Gains On Positive MS1819-PERT Combo Data In Pancreatic Insufficiency Benzinga

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

07:11AM EDT AzurRx BioPharma Announces Positive Interim Data In Phase 2 Clinical Trial Of MS1819 In Combination With PERT RTTNews

07:02AM EDT AzurRx BioPharma Announces Interim Data In Phase 2 Clinical Trial Of MS1819 In Combination With PERT; Says Data Indicate Combination Led To Clinically Meaningful Improvements In Primary Efficacy Endpoint Benzinga

07:00AM EDT Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint GlobeNewswire Inc

May 12, 2021

07:35AM EDT AzurRx BioPharma Says Receives ~$550K For 2020 CIR French Research Tax Credit Benzinga

07:30AM EDT AzurRx BioPharma Receives Approximately $550K for its 2020 CIR GlobeNewswire Inc

May 11, 2021

08:30AM EDT AzurRx BioPharma, Inc. (NASDAQ: AZRX), (AzurRx or the Company), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will make a virtual presentation at the Emerging Growth Conference taking place on Wednesday, May 12th, 2021. GlobeNewswire Inc

07:30AM EDT AzurRx BioPharma, Inc. (NASDAQ: AZRX), (AzurRx or the Company), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, AzurRx President, CEO and Chairman, will present at Investor Summit Groups Q2 Virtual Investor Summit taking place May 17-18, 2021. GlobeNewswire Inc

May 10, 2021

07:00AM EDT EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, announces the Schedule of the 7th Emerging Growth Conference. GlobeNewswire Inc

Apr 15, 2021

07:37AM EDT AzurRx BioPharma CEO Issues Letter To Shareholders Benzinga

Apr 13, 2021

08:51AM EDT AzurRx BioPharma Says Engages PPD To Manage Clinical Trial For Niclosamide As Treatment For Grade 1 Immune Checkpoint Inhibitor-Associated Colitis Benzinga

08:30AM EDT AzurRx BioPharma Engages PPD to Manage Clinical Trial for GlobeNewswire Inc

Apr 6, 2021

09:41AM EDT AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections Benzinga

07:01AM EDT AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Benzinga

07:00AM EDT RESERVOIR trial to evaluate niclosamides ability to target SARS-CoV-2 in the GI tract GlobeNewswire Inc

Apr 1, 2021

02:37PM EDT Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; AzurRx BioPharma Shares Slide Benzinga

12:04PM EDT Mid-Day Market Update: Crude Oil Rises Over 1%; BioXcel Therapeutics Shares Plummet Benzinga

09:37AM EDT Roth Capital Maintains Buy on AzurRx BioPharma, Lowers Price Target to $5 Benzinga

06:45AM EDT HC Wainwright & Co. Maintains Buy on AzurRx BioPharma, Lowers Price Target to $2.5 Benzinga

06:30AM EDT AzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study Benzinga

Mar 31, 2021

10:32PM EDT AzurRx BioPharma Inc.'s (AZRX) phase IIb study of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis did not consistently meet the primary efficacy endpoint. RTTNews

04:37PM EDT AzurRx BioPharma Says OPTION 2 Did Not Consistently Meet The Primary Efficacy Endpoint Benzinga

04:36PM EDT AzurRx BioPharma Press Release Highlights 'Key Takeaways' From Conference Call On Phase 2b OPTION 2 Trial Benzinga

04:35PM EDT AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 GlobeNewswire Inc

04:03PM EDT AzurRx BioPharma Says To Report Topline Data From Phase 2b OPTION 2 Clinical Trial Of MS1819 In Cystic Fibrosis In Conference Call Wednesday, March 31, At 4:30 EST Benzinga

04:01PM EDT AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 GlobeNewswire Inc

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 22, 2021

07:21AM EDT AzurRx BioPharma Reports Completion Of Enrollment In Phase 2 Clinical Trial Of MS1819 Plus PERT RTTNews

07:06AM EDT AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Benzinga

07:00AM EDT AzurRx BioPharma Announces Completion of Enrollment in Phase 2 GlobeNewswire Inc

Mar 16, 2021

07:10AM EDT AzurRx BioPharma Announces Completion Of Enrollment In Phase 2b OPTION 2 Clinical Trial Of MS1819 In Cystic Fibrosis; Top-line Data Expected By End Of Q1 Benzinga

07:00AM EDT AzurRx BioPharma Announces Completion of Enrollment in Phase 2b GlobeNewswire Inc

Mar 10, 2021

07:00AM EST AzurRx BioPharma to Present at the Maxim Group Emerging Growth GlobeNewswire Inc

Mar 8, 2021

08:46AM EST AzurRx BioPharma Announces $10 Million Registered Direct Offering GlobeNewswire Inc

08:27AM EST AzurRx BioPharma Announces $10M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Benzinga

07:00AM EST AzurRx BioPharma to Participate in the 33rd Annual Roth Conference GlobeNewswire Inc

Mar 2, 2021

07:00AM EST AzurRx BioPharma to Participate in Fireside GlobeNewswire Inc

Feb 24, 2021

07:04AM EST AzurRx Appoints James Sapirstein, President And CEO, As Chairman Of Board RTTNews

07:01AM EST AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors Benzinga

07:00AM EST AzurRx BioPharma Appoints President and CEO James Sapirstein as GlobeNewswire Inc

Feb 16, 2021

07:00AM EST AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinanttherapies forgastrointestinal (GI) diseases, today announced that James Sapirstein, Chief Executive Officer, will present at The Microcap Rodeo Winter Wonderland Conference taking place virtually from February 16-19, 2021. GlobeNewswire Inc

Feb 10, 2021

06:17AM EST HC Wainwright & Co. Maintains Buy on AzurRx BioPharma, Raises Price Target to $3.5 Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

06:43AM EST AzurRx BioPharma Engages PPD To Manage Clinical Trial For Niclosamide As Treatment For COVID-19 Gastrointestinal Infections Benzinga

06:30AM EST AzurRx BioPharma Engages PPD to Manage Clinical Trial for GlobeNewswire Inc

Feb 8, 2021

08:00AM EST AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference GlobeNewswire Inc

Jan 28, 2021

07:09AM EST AzurRx BioPharma Announces Completion Of Enrollment In First Cohort Of Phase 2b OPTION 2 Extension Study Of MS1819 Benzinga

07:00AM EST AzurRx BioPharma Announces Completion of Enrollment in First GlobeNewswire Inc

Jan 26, 2021

07:12AM EST AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients Benzinga

07:00AM EST AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for GlobeNewswire Inc

Jan 22, 2021

07:22AM EST The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga

Jan 21, 2021

08:06AM EST AzurRx Says First Two Patients Dosed In Phase 2b OPTION 2 Extension Study Of MS1819 RTTNews

08:05AM EST AzurRx BioPharma Announces First Two Patients Dosed In Phase 2b OPTION 2 Extension Study Of MS1819 In Cystic Fibrosis Patients Benzinga

08:00AM EST AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b GlobeNewswire Inc

Jan 13, 2021

05:35PM EST AzurRx BioPharma Files For Offering Of 16M Shares Of Common Stock By Selling Stockholder Benzinga

Jan 12, 2021

08:31AM EST AzurRx BioPharma And First Wave Bio Announce Allowance Of US Patent Application For Niclosamide As Treatment For COVID-19 Gastrointestinal Infections Benzinga

08:30AM EST AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. GlobeNewswire Inc

Jan 8, 2021

09:01AM EST AzurRx BioPharma CEO Issues Letter To Shareholders Benzinga

09:00AM EST AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinanttherapies forgastrointestinal (GI) diseases, today issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer. GlobeNewswire Inc

Jan 7, 2021

08:00AM EST AzurRx BioPharma, Inc. (NASDAQ: AZRX), (AzurRx or the Company), a company specializing in the development of targeted, non-systemictherapies forgastrointestinal (GI) diseases, today announced that the Company will be participating in this years Biotech Showcase Digital 2021 conference. GlobeNewswire Inc

Jan 4, 2021

07:05AM EST AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections Benzinga

07:04AM EST AzurRx BioPharma Announces $8M Offering Benzinga

07:00AM EST AzurRx BioPharma Announces $8.0 Million Offerings GlobeNewswire Inc

07:00AM EST AzurRx BioPharma Announces Exclusive Worldwide License Agreement GlobeNewswire Inc

Dec 7, 2020

09:27AM EST AzurRx On Dec. 4 Received Letter From Nasdaq Granting 180-Day Extension To June 1, 2021 To Regain Compliance With Listing Requirement Benzinga

Nov 30, 2020

08:03AM EST AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Benzinga

08:00AM EST -- Patient screening and dosing ongoing in Turkey and Hungary -- Topline data expected in Q2 2021 for the Combination Trial GlobeNewswire Inc

Nov 24, 2020

08:17AM EST via InvestorWire InvestorBrandNetwork(IBN), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode ofthe Stock2Me Podcastas part of its sustained effort to provide specialized content distribution via widespread syndication channels. GlobeNewswire Inc

Nov 17, 2020

08:03AM EST AzurRx BioPharma Reports Will Submit Protocol Amendment Request To FDA For Its Phase 2b OPTION 2 Trial Of MS1819 For Treatment Of Exocrine Pancreatic Insufficiency In Patients With Cystic Fibrosis Benzinga

08:00AM EST Potential to add additional study arm utilizing immediate release capsules GlobeNewswire Inc

Nov 10, 2020

08:00AM EST AzurRx BioPharma Identifies Asymchem as Potential Partner of GlobeNewswire Inc

Oct 21, 2020

08:00AM EDT -- Globally recognized experts in cystic fibrosis and chronic pancreatitis care and research to support AzurRx in advancing the clinical development of MS1819 GlobeNewswire Inc

Oct 14, 2020

08:08AM EDT AzurRx BioPharma Activates Additional Clinical Trial Sites In Turkey For Phase 2 Combination Therapy Trial Of MS1819 In Cystic Fibrosis Benzinga

08:00AM EDT -- Twoclinical trial sites activated in Turkey, with patient screening initiated -- Follows activation of six clinical sites in Hungary and dosing of first eight patients -- Topline data expected in Q2 2021 GlobeNewswire Inc

Oct 7, 2020

08:12AM EDT AzurRx Biopharma In Shareholder Letter Says Expecting Top Line Data For Phase 2 Cystic Fibrosis Combination Trial In Q2 2021; Co Discontinues AZX1103 Beta-Lactamase And MTAN Pre-Clinical Programs, Closes Laboratory In France Benzinga

08:00AM EDT AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinanttherapies forgastrointestinal diseases, today issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer. GlobeNewswire Inc

Sep 17, 2020

05:32PM EDT AzurRx BioPharma In FormRW Seeks Withdrawal Of The Registration Statement; Opted To Include Shares Being Offered As Part Of Registration Statement Benzinga

Sep 15, 2020

08:19AM EDT AzurRx BioPharma Announces Two Abstracts For Presentation At 2020 North American Cystic Fibrosis Virtual Conference Benzinga

08:01AM EDT AzurRx BioPharma Announces Two Abstracts Accepted for Presentation GlobeNewswire Inc

Aug 31, 2020

08:00AM EDT AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd GlobeNewswire Inc

Aug 17, 2020

08:13AM EDT AzurRx BioPharma Begins European Arm Of Phase 2b OPTION 2 Clinical Trial Of MS1819 RTTNews

08:02AM EDT AzurRx BioPharma Initiates European Arm Of Phase 2b OPTION 2 Clinical Trial Of MS1819 In Cystic Fibrosis Benzinga

08:00AM EDT -- Three clinical trial sites activated in Poland, with patient screening initiated -- Follows activation of six clinical sites in the U.S. and dosing of first three patients -- Topline data expected in Q1 2021 GlobeNewswire Inc

Aug 13, 2020

08:16AM EDT AzurRx BioPharma Enrolls First 3 Patients Dosed In Phase 2b OPTION 2 Clinical Trial Of MS1819 In Cystic Fibrosis RTTNews

08:15AM EDT AzurRx Says First Patients Dosed In Phase 2b OPTION 2 Clinical Trial Of MS1819 RTTNews

08:01AM EDT AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Benzinga

08:00AM EDT -- First three patients enrolled in dose escalation trial using delayed-release enteric capsules -- Topline data expected in 1H 2021 GlobeNewswire Inc

Aug 12, 2020

03:44PM EDT AzurRx BioPharma CEO Sends Letter To Shareholders Clarifying Statements Benzinga

03:44PM EDT AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinanttherapies forgastrointestinal diseases, today issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer. GlobeNewswire Inc

Aug 11, 2020

04:09PM EDT AzurRx BioPharma Announces Interim Data From Its First Patient Cohort In The Phase 2 Clinical Trial Of Its MS1819; First Five Patients Demonstrated That Its Primary And Secondary Endpoints Was Achieved Benzinga

04:01PM EDT -- Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achieved -- Clinically meaningful improvement (>80%) in coefficient of fat absorption (CFA) for all patients across all dose levels of MS1819 -- Topline data from full dataset anticipated in 1Q 2021 GlobeNewswire Inc

Jul 22, 2020

08:20AM EDT BioPharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire

08:09AM EDT AzurRx BioPharma Initiates Phase 2b Clinical Trial Of MS1819 RTTNews

08:01AM EDT AzurRx BioPharma Reports Initiation Of Phase 2b Trial Of MS1819 In Cystic Fibrosis, First Patient Screened, 3 Sites Activated; Sees Topline data Q1'21 Benzinga

08:00AM EDT -- Three OPTION 2 clinical trial sites activated in the U.S. -- Topline data expected in Q1 2021 GlobeNewswire Inc

Jul 20, 2020

08:00AM EDT -- Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosis -- Exchange of $6.9 million principal amount of outstanding promissory notes into private placement strengthens balance sheet GlobeNewswire Inc

Share